Neurogene (NGNE) News Today $22.64 +0.56 (+2.54%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Short Interest in Neurogene Inc. (NASDAQ:NGNE) Drops By 28.7%Neurogene Inc. (NASDAQ:NGNE - Get Free Report) was the recipient of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 1,170,000 shares, a decline of 28.7% from the November 15th total of 1,640,000 shares. Based on an average daily volume of 348,300 shares, the short-interest ratio is presently 3.4 days. Currently, 10.2% of the shares of the company are short sold.December 13, 2024 | marketbeat.comWilliam Blair Reaffirms Their Buy Rating on Neurogene (NGNE)December 13, 2024 | markets.businessinsider.comNeurogene Inc. (NASDAQ:NGNE) Given Average Rating of "Buy" by AnalystsShares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have earned an average recommendation of "Buy" from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating and one has issued a strongDecember 12, 2024 | marketbeat.comFmr LLC Grows Stock Holdings in Neurogene Inc. (NASDAQ:NGNE)Fmr LLC boosted its stake in Neurogene Inc. (NASDAQ:NGNE - Free Report) by 912.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 731,801 shares of the company's stock after buying an additional 659,515 shares duDecember 9, 2024 | marketbeat.comJanus Henderson Group PLC Reduces Holdings in Neurogene Inc. (NASDAQ:NGNE)Janus Henderson Group PLC lowered its stake in Neurogene Inc. (NASDAQ:NGNE - Free Report) by 15.0% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 709,469 shares of the company's stock after selling 125,322 shares during tDecember 7, 2024 | marketbeat.comNeurogene Inc. (NASDAQ:NGNE) Shares Acquired by RTW Investments LPRTW Investments LP grew its stake in Neurogene Inc. (NASDAQ:NGNE - Free Report) by 6.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,135,256 shares of the company's stock after purchasing an additionalDecember 5, 2024 | marketbeat.comRedmile Group LLC Sells 49,316 Shares of Neurogene Inc. (NASDAQ:NGNE)Redmile Group LLC reduced its position in Neurogene Inc. (NASDAQ:NGNE - Free Report) by 4.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 964,347 shares of the company's stock after selling 49,316 sharesDecember 5, 2024 | marketbeat.comWalleye Capital LLC Reduces Stock Position in Neurogene Inc. (NASDAQ:NGNE)Walleye Capital LLC lessened its stake in shares of Neurogene Inc. (NASDAQ:NGNE - Free Report) by 51.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,500 shares of the company's stock afDecember 5, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNEDecember 3, 2024 | prnewswire.comNeurogene Inc. (NASDAQ:NGNE) Major Shareholder Acquires $1,259,729.10 in StockNovember 28, 2024 | insidertrades.comPositive Outlook on Neurogene’s NGN-401 Despite Setback: Buy Rating Reaffirmed with $55 Price TargetNovember 26, 2024 | markets.businessinsider.comNeurogene and Ventyx Biosciences rises after insider buying by executivesNovember 26, 2024 | msn.comNeurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic Acquires 24,000 SharesNovember 26, 2024 | insidertrades.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNENovember 25, 2024 | prnewswire.comHC Wainwright Reaffirms Buy Rating for Neurogene (NASDAQ:NGNE)HC Wainwright reiterated a "buy" rating and issued a $55.00 price objective on shares of Neurogene in a research note on Monday.November 25, 2024 | marketbeat.comNeurogene reports patient death in Rett syndrome trialNovember 23, 2024 | investing.comJennison Associates LLC Takes Position in Neurogene Inc. (NASDAQ:NGNE)Jennison Associates LLC purchased a new position in Neurogene Inc. (NASDAQ:NGNE - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 78,650 shares of the company's stock, valuedNovember 23, 2024 | marketbeat.comNeurogene’s Proactive Clinical and Financial Strength Supports Buy Rating with $72 TargetNovember 22, 2024 | markets.businessinsider.comNeurogene’s Resilient Clinical Progress and Strong Financial Position Support Buy RatingNovember 22, 2024 | markets.businessinsider.comFY2024 EPS Estimates for Neurogene Raised by HC WainwrightNeurogene Inc. (NASDAQ:NGNE - Free Report) - HC Wainwright boosted their FY2024 earnings estimates for shares of Neurogene in a report released on Tuesday, November 19th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($4.34) per share for the year, up from their prior estNovember 21, 2024 | marketbeat.comNeurogene FY2024 EPS Estimate Reduced by Leerink PartnrsNeurogene Inc. (NASDAQ:NGNE - Free Report) - Investment analysts at Leerink Partnrs cut their FY2024 earnings estimates for shares of Neurogene in a research report issued on Monday, November 18th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share ofNovember 21, 2024 | marketbeat.comFY2024 EPS Estimates for Neurogene Lowered by William BlairNeurogene Inc. (NASDAQ:NGNE - Free Report) - Stock analysts at William Blair decreased their FY2024 earnings estimates for shares of Neurogene in a research report issued to clients and investors on Tuesday, November 19th. William Blair analyst S. Corwin now forecasts that the company will post eNovember 21, 2024 | marketbeat.comPromising Outlook for Neurogene’s Low-Dose NGN-401 Program in Rett SyndromeNovember 20, 2024 | markets.businessinsider.comNeurogene price target lowered to $45 from $60 at BMO CapitalNovember 20, 2024 | markets.businessinsider.comNeurogene Inc. Faces Uncertainty with NGN-101 Program Amid FDA Challenges and Strategic HurdlesNovember 20, 2024 | tipranks.comNeurogene (NASDAQ:NGNE) Earns Outperform Rating from William BlairWilliam Blair reissued an "outperform" rating on shares of Neurogene in a research note on Tuesday.November 19, 2024 | marketbeat.comNeurogene (NASDAQ:NGNE) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $55.00 target price on shares of Neurogene in a research note on Tuesday.November 19, 2024 | marketbeat.comPositive Buy Rating for Neurogene Driven by Promising Low-Dose NGN-401 Results and Proactive Safety MeasuresNovember 18, 2024 | markets.businessinsider.comNeurogene provides update on NGN-401 clinical trial for Rett syndromeNovember 18, 2024 | markets.businessinsider.comNeurogene stock plunges 36% on NGN-401 study updateNovember 18, 2024 | seekingalpha.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNENovember 18, 2024 | prnewswire.comNeurogene Reports Third Quarter 2024 Financial Results and Highlights Recent UpdatesNovember 18, 2024 | businesswire.comNeurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett SyndromeNovember 18, 2024 | businesswire.comNeurogene Inc. (NASDAQ:NGNE) Given Average Recommendation of "Buy" by AnalystsShares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have been assigned a consensus rating of "Buy" from the nine brokerages that are covering the stock, MarketBeat reports. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on theNovember 17, 2024 | marketbeat.comNeurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks.November 14, 2024 | marketbeat.comNeurogene reports ‘positive’ interim efficacy data from NGN-401 participantsNovember 12, 2024 | markets.businessinsider.comNeurogene Shares Drop 35% on Rett Syndrome Gene Therapy Trial DataNovember 12, 2024 | finance.yahoo.comNeurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy TrialNovember 12, 2024 | benzinga.comLeerink Partners Forecasts Strong Price Appreciation for Neurogene (NASDAQ:NGNE) StockLeerink Partners raised their price objective on Neurogene from $45.00 to $72.00 and gave the stock an "outperform" rating in a research report on Tuesday.November 12, 2024 | marketbeat.comNeurogene (NASDAQ:NGNE) Price Target Raised to $55.00 at HC WainwrightHC Wainwright increased their price objective on shares of Neurogene from $49.00 to $55.00 and gave the stock a "buy" rating in a research note on Tuesday.November 12, 2024 | marketbeat.comRobert W. Baird Increases Neurogene (NASDAQ:NGNE) Price Target to $72.00Robert W. Baird boosted their price target on Neurogene from $54.00 to $72.00 and gave the stock an "outperform" rating in a report on Tuesday.November 12, 2024 | marketbeat.comNeurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett SyndromeNovember 11, 2024 | businesswire.comNeurogene (NASDAQ:NGNE) Hits New 52-Week High - Should You Buy?Neurogene (NASDAQ:NGNE) Reaches New 12-Month High - Here's WhyNovember 11, 2024 | marketbeat.comNeurogene: Interesting CNS Disease Company, Data Coming SoonNovember 10, 2024 | seekingalpha.comFY2024 EPS Estimates for Neurogene Boosted by AnalystNeurogene Inc. (NASDAQ:NGNE - Free Report) - Equities researchers at Leerink Partnrs lifted their FY2024 earnings estimates for Neurogene in a note issued to investors on Monday, November 4th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($4.40) per share for theNovember 7, 2024 | marketbeat.comNeurogene (NASDAQ:NGNE) Stock Quotes, Forecast and News SummaryNovember 6, 2024 | benzinga.comNeurogene (NASDAQ:NGNE) Sees Strong Trading Volume - Should You Buy?Neurogene (NASDAQ:NGNE) Sees Strong Trading Volume - Still a Buy?November 5, 2024 | marketbeat.comNeurogene Secures $200M for Genetic Therapy DevelopmentNovember 5, 2024 | markets.businessinsider.comNeurogene (NASDAQ:NGNE) Stock, Option ChainNovember 5, 2024 | benzinga.comLe titre NGNE atteint un sommet de 52 semaines à 56,17$, porté par une forte croissanceNovember 4, 2024 | fr.investing.com Get Neurogene News Delivered to You Automatically Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Buy this coin BEFORE Inauguration Day … (Ad)Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office. This could be his favorite coin. NGNE Media Mentions By Week NGNE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NGNE News Sentiment▼0.320.61▲Average Medical News Sentiment NGNE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NGNE Articles This Week▼03▲NGNE Articles Average Week Get Neurogene News Delivered to You Automatically Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MESO News TVTX News NTLA News PRAX News ARVN News DAWN News ARDX News SYRE News CALT News SNDX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NGNE) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NGNE Stock Alerts